Predictive factors for EGFR-tyrosine kinase inhibitor retreatment in patients with EGFR-mutated non-small-cell lung cancer – A multicenter retrospective SEQUENCE study

Lung Cancer

Volumn 104, Issue , 2017, Pages 58-64

  Chang, Gee Chen ^a,b   Tseng, Chien Hua ^c,d   Hsu, Kuo Hsuan ^b,d   Yu, Chong Jen ^e   Yang, Cheng Ta ^f   Chen, Kun Chieh ^a,b   Yang, Tsung Ying ^a   Tseng, Jeng Sen ^a   Liu, Chien Ying ^e   Liao, Wei Yu ^f   Hsia, Te Chun ^g   Tu, Chih Yen ^g   Lin, Meng Chih ^h   Tsai, Ying Huang ^f   Hsieh, Meng Jer ^f   Wu, Wen Shuo ^a   Chen, Yuh Min ^a  

^a NATIONAL YANG MING UNIVERSITY   (Taiwan)

^b NATIONAL CHUNG HSING UNIVERSITY   (Taiwan)

^c NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^d TAICHUNG VETERANS GENERAL HOSPITAL   (Taiwan)

^e NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^f CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^g CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^h CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

Author keywords

Adenocarcinoma; Drug holiday; EGFR mutation; EGFR TKI retreatment; Exon 21 mutation; Females; Lung cancer; Overall survival; Progression free survival

Indexed keywords

AFATINIB; ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GEFITINIB; THYROID TRANSCRIPTION FACTOR 1; EGFR PROTEIN, HUMAN; NUCLEAR PROTEIN; PROTEIN KINASE INHIBITOR; THYROID NUCLEAR FACTOR 1; TRANSCRIPTION FACTOR;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER CONTROL; CANCER PATIENT; CANCER REGRESSION; CANCER SURVIVAL; EXON; FEMALE; GENE MUTATION; HUMAN; LUNG ADENOCARCINOMA; LUNG CARCINOGENESIS; MAJOR CLINICAL STUDY; MALE; MOLECULARLY TARGETED THERAPY; NON SMALL CELL LUNG CANCER; OVERALL SURVIVAL; PREDICTION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RETREATMENT; RETROSPECTIVE STUDY; TREATMENT RESPONSE; ADENOCARCINOMA; CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIAL; DISEASE FREE SURVIVAL; GENETICS; LUNG NEOPLASMS; MIDDLE AGED; MULTICENTER STUDY; MUTATION; PATHOLOGY; PREDICTIVE VALUE; SECONDARY; TREATMENT OUTCOME; VERY ELDERLY;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; DISEASE-FREE SURVIVAL; EXONS; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MUTATION; NUCLEAR PROTEINS; PREDICTIVE VALUE OF TESTS; PROTEIN KINASE INHIBITORS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RETREATMENT; RETROSPECTIVE STUDIES; TRANSCRIPTION FACTORS; TREATMENT OUTCOME;

EID: 85007199720     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2016.12.002     Document Type: Article

References (36)

1. [1] Mok, T.S., Wu, Y.L., Thongprasert, S., et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N. Engl. J. Med. 361:September (10) (2009), 947–957.
2. [2] Maemondo, M., Inoue, A., Kobayashi, K., et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N. Engl. J. Med. 362:June (25) (2010), 2380–2388.
3. [3] Mitsudomi, T., Morita, S., Yatabe, Y., et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol. 11:February (2) (2010), 121–128.
4. [4] Rosell, R., Carcereny, E., Gervais, R., et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 13:March (3) (2012), 239–246.
5. [5] Yang, J.C., Shih, J.Y., Su, W.C., et al. Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): a phase 2 trial. Lancet Oncol. 13:May (5) (2012), 539–548.
6. [6] Thongprasert, S., Duffield, E., Saijo, N., et al. Health-related quality-of-life in a randomized phase III first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients from Asia with advanced NSCLC (IPASS). J. Thorac. Oncol. 6:November (11) (2011), 1872–1880.
7. [7] Oizumi, S., Kobayashi, K., Inoue, A., et al. Quality of life with gefitinib in patients with EGFR-mutated non-small cell lung cancer: quality of life analysis of North East Japan Study Group 002 Trial. Oncologist 17:6 (2012), 863–870.
8. [8] Oxnard, G.R., Arcila, M.E., Chmielecki, J., Ladanyi, M., Miller, V.A., Pao, W., New strategies in overcoming acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in lung cancer. Clin. Cancer Res. 17:September (17) (2011), 5530–5537.
9. [9] Becker, A., Crombag, L., Heideman, D.A., et al. Retreatment with erlotinib: regain of TKI sensitivity following a drug holiday for patients with NSCLC who initially responded to EGFR-TKI treatment. Eur. J. Cancer 47:November (17) (2011), 2603–2606.
10. [10] Xia, G.H., Zeng, Y., Fang, Y., et al. Effect of EGFR-TKI retreatment following chemotherapy for advanced non-small cell lung cancer patients who underwent EGFR-TKI. Cancer Biol. Med. 11:December (4) (2014), 270–276.
11. [11] Kaira, K., Naito, T., Takahashi, T., et al. Pooled analysis of the reports of erlotinib after failure of gefitinib for non-small cell lung cancer. Lung Cancer 68:April (1) (2010), 99–104.
12. [12] Eisenhauer, E.A., Therasse, P., Bogaerts, J., et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur. J. Cancer 45:January (2) (2009), 228–247.
13. [13] Piotrowska, Z., Sequist, L.V., Treatment of EGFR-mutant lung cancers after progression in patients receiving first-line EGFR tyrosine kinase inhibitors: a review. JAMA Oncol.(May (19)), 2016.
14. [14] Guo, R., Chen, X., Wang, T., Zhang, Z., Sun, J., Shu, Y., Subsequent chemotherapy reverses acquired tyrosine kinase inhibitor resistance and restores response to tyrosine kinase inhibitor in advanced non-small-cell lung cancer. BMC Cancer, 11, 2011, 90.
15. [15] Li, X.D., Geng, Y.T., Wu, C.P., et al. Restoration of gefitinib efficacy following chemotherapy in a patient with metastatic non-small cell lung cancer. Onkologie 33:8–9 (2010), 466–469.
16. [16] Yoshimoto, A., Inuzuka, K., Kita, T., Kawashima, A., Kasahara, K., Remarkable effect of gefitinib retreatment in a patient with nonsmall cell lung cancer who had a complete response to initial gefitinib. Am. J. Med. Sci. 333:April (4) (2007), 221–225.
17. [17] Sabaawy, H.E., Genetic heterogeneity and clonal evolution of tumor cells and their impact on precision cancer medicine. J. Leuk., 1(November (4)), 2013, 1000124.
18. [18] Tomizawa, Y., Fujita, Y., Tamura, A., et al. Effect of gefitinib re-challenge to initial gefitinib responder with non-small cell lung cancer followed by chemotherapy. Lung Cancer 68:May (2) (2010), 269–272.
19. [19] Yokouchi, H., Yamazaki, K., Kinoshita, I., et al. Clinical benefit of readministration of gefitinib for initial gefitinib-responders with non-small cell lung cancer. BMC Cancer, 7, 2007, 51.
20. [20] Sequist, L.V., Waltman, B.A., Dias-Santagata, D., et al. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci. Transl. Med., 3(March (75)), 2011 75ra26.
21. [21] Yu, H.A., Arcila, M.E., Rekhtman, N., et al. Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers. Clin. Cancer Res. 19:April (8) (2013), 2240–2247.
22. [22] Oh, I.J., Ban, H.J., Kim, K.S., Kim, Y.C., Retreatment of gefitinib in patients with non-small-cell lung cancer who previously controlled to gefitinib: a single-arm, open-label, phase II study. Lung Cancer 77:July (1) (2012), 121–127.
23. [23] Hata, A., Katakami, N., Yoshioka, H., et al. Erlotinib after gefitinib failure in relapsed non-small cell lung cancer: clinical benefit with optimal patient selection. Lung Cancer 74:November (2) (2011), 268–273.
24. [24] Lee, V.H., Leung, D.K., Choy, T.S., et al. Efficacy and safety of afatinib in Chinese patients with EGFR-mutated metastatic non-small-cell lung cancer (NSCLC) previously responsive to first-generation tyrosine-kinase inhibitors (TKI) and chemotherapy: comparison with historical cohort using erlotinib. BMC Cancer, 16, 2016, 147.
25. [25] Koizumi, T., Agatsuma, T., Ikegami, K., et al. Prospective study of gefitinib readministration after chemotherapy in patients with advanced non-small-cell lung cancer who previously responded to gefitinib. Clin. Lung Cancer 13:November (6) (2012), 458–463.
26. [26] Zhao, Z.R., Li, W., Long, H., Readministration of EGFR tyrosine kinase inhibitor in non-small cell lung cancer patients after initial failure, what affects its efficacy?. Sci. Rep., 4, 2014, 5996.
27. [27] Zhang, Y., Sheng, J., Kang, S., et al. Patients with exon 19 deletion were associated with longer progression-free survival compared to those with L858R mutation after first-line EGFR-TKIs for advanced non-small cell lung cancer: a meta-analysis. PLoS One, 9(9), 2014, e107161.
28. [28] Hidalgo, M., Siu, L.L., Nemunaitis, J., et al. Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies. J. Clin. Oncol. 19:July (13) (2001), 3267–3279.
29. [29] Ranson, M., Hammond, L.A., Ferry, D., et al. ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: results of a phase I trial. J. Clin. Oncol. 20:May (9) (2002), 2240–2250.
30. [30] Popat, S., Mok, T., Yang, J.C., et al. Afatinib in the treatment of EGFR mutation-positive NSCLC–a network meta-analysis. Lung Cancer 85:August (2) (2014), 230–238.
31. [31] Liang, W., Wu, X., Fang, W., et al. Network meta-analysis of erlotinib, gefitinib, afatinib and icotinib in patients with advanced non-small-cell lung cancer harboring EGFR mutations. PLoS One, 9(2), 2014, e85245.
32. [32] Lee, C.K., Wu, Y.L., Ding, P.N., et al. Impact of specific epidermal growth factor receptor (EGFR) mutations and clinical characteristics on outcomes after treatment with EGFR tyrosine kinase inhibitors versus chemotherapy in EGFR-mutant lung cancer: a meta-analysis. J. Clin. Oncol. 33:June (17) (2015), 1958–1965.
33. [33] Nose, N., Sugio, K., Oyama, T., et al. Association between estrogen receptor-beta expression and epidermal growth factor receptor mutation in the postoperative prognosis of adenocarcinoma of the lung. J. Clin. Oncol. 27:January (3) (2009), 411–417.
34. [34] Yang, S.Y., Yang, T.Y., Chen, K.C., et al. EGFR L858R mutation and polymorphisms of genes related to estrogen biosynthesis and metabolism in never-smoking female lung adenocarcinoma patients. Clin. Cancer Res. 17:April (8) (2011), 2149–2158.
35. [35] Katakami, N., Atagi, S., Goto, K., et al. LUX-Lung 4: a phase II trial of afatinib in patients with advanced non-small-cell lung cancer who progressed during prior treatment with erlotinib, gefitinib, or both. J. Clin. Oncol. 31:September (27) (2013), 3335–3341.
36. [36] Miller, V.A., Hirsh, V., Cadranel, J., et al. Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial. Lancet Oncol. 13:May (5) (2012), 528–538.